Boston Common Asset Management’s BioNTech BNTX Stock Holding History

Boston Common Asset Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-25,771	Closed	-$2.38M	–	314
2024 Q1	$2.38M	Sell	25,771 -6,599	-20%	-$633K	0.06%	251
2023 Q4	$3.42M	Sell	32,370 -120,620	-79%	-$12.2M	0.08%	227
2023 Q3	$16.6M	Sell	152,990 -92,395	-38%	-$10.2M	0.4%	96
2023 Q2	$26.5M	Sell	245,385 -19,257	-7%	-$2.17M	0.57%	70
2023 Q1	$33M	Sell	264,642 -5,161	-2%	-$709K	0.69%	49
2022 Q4	$40.5M	Sell	269,803 -10,084	-4%	-$1.55M	1.94%	4
2022 Q3	$37.8M	Sell	279,887 -3,889	-1%	-$595K	1.98%	4
2022 Q2	$42.3M	Buy	283,776 +3,595	+1%	+$549K	2.11%	4
2022 Q1	$47.8M	Buy	280,181 +87,511	+45%	+$14.7M	2.06%	6
2021 Q4	$49.7M	Buy	+192,670	New	+$52.8M	2.01%	6

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boston Common Asset Management's BNTX Position: Q2 2024 in Review

Boston Common Asset Management sold out of BioNTech (BNTX) in Q2 2024, closing a stake of 25,771 shares — an estimated $2.38M sold.

Boston Common Asset Management first reported a position in BNTX in Q4 2021 and held it in 10 quarters. The position peaked at $49.7M in Q4 2021. 286 funds tracked by Wall St. Rank hold BNTX as of Q2 2024.

Boston Common Asset Management reported no remaining BioNTech position as of Q2 2024 after selling out during the quarter.
Boston Common Asset Management sold 25,771 BioNTech shares in Q2 2024, an estimated $2.38M.
Boston Common Asset Management first reported a position in BioNTech in Q4 2021 and held it in 10 quarters.
Boston Common Asset Management's BioNTech position peaked at $49.7M in Q4 2021.
286 funds tracked by Wall St. Rank held BioNTech as of Q2 2024.

Based on Boston Common Asset Management's 13F filing for Q2 2024, filed 8 Jul 2024.